Table 1. Pharmacokinetics parameters of hPTH(1–34) and PCO371 in normal rats.
| Route | Dose | T1/2 | Tmax | Cmax | AUCinf | BA | |
|---|---|---|---|---|---|---|---|
| (h) | (h) | (ng ml−1) | (ng h ml−1) | % | |||
| hPTH(1–34) (nmol kg−1) | s.c. | 3 | 0.3±0.1 | 0.1±0.1 | 2.42±0.53 | 0.99±0.17 | 22 |
| PCO371 (mg kg−1) | p.o. | 2 | 1.5±0.1 | 1.5±0.9 | 92.5±37.1 | 374±187 | 34 |
| 6 | 1.4±0.2 | 1.0±0.0 | 727±103 | 2,360±280 | NE | ||
| 18 | 1.7±0.3 | 1.3±0.6 | 4,560±710 | 18,600±1,900 | NE |
NE, not examined; BA, bioavailability.
Rats were treated with a single subcutaneous injection of hPTH(1–34), or a single oral administration of PCO371. Blood samples were collected at 2, 5, 10, 15, 30 and 45 min, and 1 and 2 h [for hPTH(1–34)] or at 15 and 30 min, and 1, 2, 4, 6, and 24 h (for PCO371), and pharmacokinetics parameters were determined. Data are represented as the mean±s.d. of one experiment (n=3 for PCO371, n=4 for hPTH(1–34)).